A detailed history of Silvercrest Asset Management Group LLC transactions in Exagen Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 540,888 shares of XGN stock, worth $2.79 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
540,888
Previous 544,877 0.73%
Holding current value
$2.79 Million
Previous $991,000 68.62%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.74 - $3.42 $6,940 - $13,642
-3,989 Reduced 0.73%
540,888 $1.67 Million
Q2 2024

Aug 14, 2024

SELL
$1.36 - $2.05 $741,032 - $1.12 Million
-544,877 Reduced 50.0%
544,877 $991,000
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.05 $741,032 - $1.12 Million
544,877 Added 100.0%
1,089,754 $1.98 Million
Q3 2023

Nov 14, 2023

SELL
$2.24 - $2.93 $5,053 - $6,610
-2,256 Reduced 0.41%
544,877 $1.32 Million
Q2 2023

Aug 14, 2023

BUY
$2.36 - $3.48 $105,062 - $154,922
44,518 Added 8.86%
547,133 $1.59 Million
Q4 2022

Feb 14, 2023

SELL
$2.1 - $3.4 $9,435 - $15,276
-4,493 Reduced 0.89%
502,615 $1.21 Million
Q3 2022

Nov 14, 2022

BUY
$2.69 - $8.68 $30,988 - $99,993
11,520 Added 2.32%
507,108 $1.37 Million
Q2 2022

Aug 15, 2022

SELL
$4.18 - $7.74 $92,081 - $170,504
-22,029 Reduced 4.26%
495,588 $2.85 Million
Q1 2022

May 16, 2022

BUY
$7.12 - $11.06 $33,656 - $52,280
4,727 Added 0.92%
517,617 $4.16 Million
Q3 2021

Nov 15, 2021

BUY
$10.25 - $15.21 $2.08 Million - $3.08 Million
202,692 Added 65.34%
512,890 $6.98 Million
Q2 2021

Aug 16, 2021

SELL
$12.4 - $17.92 $15,586 - $22,525
-1,257 Reduced 0.4%
310,198 $4.65 Million
Q1 2021

May 17, 2021

BUY
$13.9 - $22.0 $4.33 Million - $6.85 Million
311,455 New
311,455 $5.45 Million

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $83.7M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.